Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Zoetis Inc. ZTS

Healthcare — Drug Manufacturers Specialty & Generic
S&P 500 Member Dividend Champion (3y) Insider Buys (last 12m)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

Zoetis Inc. (ZTS) Business Profile

Company Overview

Zoetis Inc. (NYSE: ZTS) is a global leader in the animal health industry, dedicated to the discovery, development, manufacture, and commercialization of veterinary medicines and vaccines. The company was originally a part of Pfizer, operating as its animal health division, but became an independent entity in 2013 following a successful initial public offering (IPO). Headquartered in Parsippany, New Jersey, Zoetis has a presence in over 100 countries and employs more than 13,000 people worldwide. The company is led by Kristin Peck, who has served as Chief Executive Officer since January 2020. Under her leadership, Zoetis has continued to expand its portfolio and strengthen its position as a market leader in animal health.

Core Business Segments

Zoetis operates across several core business segments, offering a wide range of products and services designed to improve the health and well-being of animals. These segments include:

1. Livestock Products

Zoetis provides a comprehensive portfolio of products for livestock, including cattle, swine, poultry, sheep, and fish. Key offerings include:

  • Vaccines: Products like Bovi-Shield and Suvaxyn help prevent diseases in livestock.
  • Anti-Infectives: Medications such as Draxxin and Excede are used to treat bacterial infections.
  • Parasiticides: Solutions like Dectomax and Valbazen combat parasites in livestock.
  • Other Products: Nutritional additives and diagnostics tailored for livestock health.

2. Companion Animal Products

Zoetis is a leader in the companion animal market, offering products for pets such as dogs, cats, and horses. Key offerings include:

  • Vaccines: Vanguard and ProHeart are widely used to protect pets from diseases.
  • Parasiticides: Simparica Trio and Revolution Plus are popular for flea, tick, and heartworm prevention.
  • Dermatology Products: Apoquel and Cytopoint are innovative solutions for treating allergic skin conditions in pets.
  • Pain Management: Products like Rimadyl and Librela help manage pain in aging or injured animals.

3. Diagnostics

Zoetis has a growing diagnostics segment, offering advanced tools and technologies to veterinarians. This includes:

  • Point-of-Care Diagnostics: Devices like Vetscan and Imagyst provide rapid and accurate diagnostic results.
  • Reference Lab Services: Comprehensive testing services for veterinary clinics.

4. Biodevices and Other Services

Zoetis also offers biodevices and other services to support animal health. These include:

  • Precision Livestock Farming: Tools like Smartbow for monitoring livestock health and behavior.
  • Genetics: Genetic testing and services to improve breeding outcomes.

Business Model

Zoetis operates on a vertically integrated business model, encompassing research and development (R&D), manufacturing, and distribution. The company invests heavily in R&D to develop innovative products and solutions, spending approximately 7-8% of its annual revenue on this area. Zoetis generates revenue through the sale of its products to veterinarians, livestock producers, and pet owners. The company also leverages its diagnostics and biodevices to create recurring revenue streams. By maintaining strong relationships with veterinary professionals and leveraging its global distribution network, Zoetis ensures its products reach customers efficiently.

Strategic Direction

Zoetis is focused on several strategic priorities to drive future growth:

  • Innovation: The company aims to expand its portfolio with new vaccines, parasiticides, and dermatology products. It is also investing in precision livestock farming and digital tools.
  • Geographic Expansion: Zoetis is targeting growth in emerging markets, particularly in Asia and Latin America.
  • Sustainability: The company has committed to reducing its environmental footprint, including achieving carbon neutrality in its operations by 2030.
  • Diagnostics Growth: Zoetis plans to expand its diagnostics segment through new product launches and acquisitions.

Competitive Landscape

Zoetis operates in a competitive market, facing challenges from both large pharmaceutical companies and specialized animal health firms. Key competitors include:

  • Elanco Animal Health: A major player in both livestock and companion animal markets.
  • Boehringer Ingelheim Animal Health: Known for its strong portfolio of vaccines and parasiticides.
  • Merck Animal Health: Offers a wide range of products, including vaccines and diagnostics.
  • IDEXX Laboratories: A leader in veterinary diagnostics.

Despite the competition, Zoetis maintains a strong market position due to its broad product portfolio, innovation capabilities, and global reach.

Risk Factors

Zoetis faces several risks that could impact its business:

  • Market Dependence: The company relies heavily on the livestock and companion animal markets, which are influenced by economic conditions and consumer spending.
  • Regulatory Challenges: Compliance with stringent regulations in different countries can be complex and costly.
  • Supply Chain Disruptions: Global supply chain issues, including raw material shortages, could affect production and distribution.
  • Competition: Intense competition may pressure pricing and margins.

Recent Developments

Zoetis has made several notable advancements in recent years:

  • Product Launches: The company introduced Librela, a monoclonal antibody for osteoarthritis pain in dogs, and Simparica Trio, a combination parasiticide for dogs.
  • Acquisitions: Zoetis acquired Fish Vet Group to strengthen its aquaculture portfolio.
  • Sustainability Initiatives: The company announced plans to achieve carbon neutrality by 2030 and reduce water usage in its operations.
  • Digital Tools: Zoetis launched new digital platforms to support veterinarians and livestock producers.

Investment Considerations

Strengths:

  • Market leader with a diverse product portfolio.
  • Strong R&D capabilities and innovation pipeline.
  • Global presence with a robust distribution network.
  • Growing diagnostics and digital tools segments.

Risks:

  • Dependence on livestock and companion animal markets.
  • Exposure to regulatory and supply chain risks.
  • Intense competition in the animal health industry.

Conclusion

Zoetis Inc. is a market leader in the animal health industry, offering a diverse range of products and services for livestock and companion animals. With a strong focus on innovation, sustainability, and geographic expansion, the company is well-positioned for future growth. While it faces risks such as regulatory challenges and supply chain disruptions, Zoetis’s strengths in R&D, global reach, and market leadership make it an attractive investment opportunity for those seeking exposure to the growing animal health sector.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us